QRG Capital Management Inc. Purchases 21,399 Shares of Bristol Myers Squibb Company $BMY

QRG Capital Management Inc. lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 291,207 shares of the biopharmaceutical company's stock after acquiring an additional 21,399 shares during the period. QRG Capital Management Inc.'s holdings in Bristol Myers Squibb were worth $15,708,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pinnacle Wealth Management Advisory Group LLC lifted its stake in Bristol Myers Squibb by 90.8% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 29,946 shares of the biopharmaceutical company's stock valued at $1,615,000 after purchasing an additional 14,253 shares during the last quarter. Varma Mutual Pension Insurance Co lifted its stake in Bristol Myers Squibb by 15.4% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 353,026 shares of the biopharmaceutical company's stock valued at $19,042,000 after purchasing an additional 47,200 shares during the last quarter. Peregrine Asset Advisers Inc. lifted its stake in Bristol Myers Squibb by 25.6% in the 4th quarter. Peregrine Asset Advisers Inc. now owns 24,687 shares of the biopharmaceutical company's stock valued at $1,332,000 after purchasing an additional 5,033 shares during the last quarter. Seizert Capital Partners LLC lifted its stake in Bristol Myers Squibb by 5.4% in the 4th quarter. Seizert Capital Partners LLC now owns 758,117 shares of the biopharmaceutical company's stock valued at $40,893,000 after purchasing an additional 38,725 shares during the last quarter. Finally, Reynders McVeigh Capital Management LLC lifted its stake in Bristol Myers Squibb by 5.3% in the 4th quarter. Reynders McVeigh Capital Management LLC now owns 17,792 shares of the biopharmaceutical company's stock valued at $960,000 after purchasing an additional 900 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company's stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers launched a global "Won't Lose" media campaign ahead of the FIFA World Cup 2026 — a brand/awareness push that investors may view as supportive for long‑term patient/brand engagement. Bristol Myers Squibb Launches “Won't-Lose” Media Campaign
• Positive Sentiment: Slimming COVID tailwinds but continued product momentum across peers: Pfizer beat Q1 estimates and reaffirmed guidance, which supports healthcare-sector sentiment and can help lift large-cap pharma multiples. Pfizer Beats Earnings Estimates. The Drugmaker Is Finding Life After Covid.
• Neutral Sentiment: Zacks reports heightened investor attention in BMY—useful as a gauge of retail/analyst focus but not a direct fundamental change. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention
• Neutral Sentiment: Broader biotech restructuring: BioNTech is cutting ~22% of its workforce as it refocuses post‑COVID — a sector data point on how companies are adjusting, but not directly tied to BMY’s pipeline. BioNTech to Slash 22% of Workforce
• Negative Sentiment: Clinical setback for BMY’s franchise: Cytokinetics reported positive results for its myosin inhibitor in non-obstructive hypertrophic cardiomyopathy, a success where Bristol Myers’ Camzyos previously failed—this opens a large market opportunity for the rival and increases competitive risk to BMY’s heart‑failure strategy. Cytokinetics heart drug scores in closely watched trial
• Negative Sentiment: Analyst stance unchanged: Scotiabank maintained a Hold rating on BMY, signaling no immediate upgrade catalyst from that firm and limiting upside from analyst momentum. Scotiabank Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BMY shares. Scotiabank reissued a "sector perform" rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a research note on Thursday, April 9th. Morgan Stanley reissued an "underweight" rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Wells Fargo & Company reissued an "outperform" rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Trading Down 0.8%

Shares of NYSE BMY opened at $56.94 on Wednesday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The firm has a 50 day moving average price of $59.48 and a two-hundred day moving average price of $54.72. The stock has a market cap of $116.28 billion, a P/E ratio of 15.99, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analysts' expectations of $10.93 billion. During the same period in the prior year, the company posted $1.80 EPS. The company's revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.29 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.